Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Inflammatory Activity on Natalizumab Predicts Short-Term but Not Long-Term Disability in Multiple Sclerosis.

Raffel J, Gafson AR, Dahdaleh S, Malik O, Jones B, Nicholas R.

PLoS One. 2017 Jan 12;12(1):e0169546. doi: 10.1371/journal.pone.0169546. eCollection 2017.

2.

Anti-JC virus antibody titres increase over time with natalizumab treatment.

Raffel J, Gafson AR, Malik O, Nicholas R.

Mult Scler. 2015 Dec;21(14):1833-8. doi: 10.1177/1352458515599681. Epub 2015 Oct 8.

3.

CCSVI-A. A call to clinicans and scientists to vocalise in an Internet age.

Gafson AR, Giovannoni G.

Mult Scler Relat Disord. 2014 Mar;3(2):143-6. doi: 10.1016/j.msard.2013.10.005. Epub 2013 Oct 22.

PMID:
25878001
4.

Towards the incorporation of lumbar puncture into clinical trials for multiple sclerosis.

Gafson AR, Giovannoni G.

Mult Scler. 2012 Oct;18(10):1509-11. Epub 2012 Feb 1. No abstract available.

PMID:
22298590
5.

Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.

Gafson AR, Goodkin O, Begent R.

BMJ Case Rep. 2010 Nov 9;2010. pii: bcr0420102869. doi: 10.1136/bcr.04.2010.2869.

Supplemental Content

Loading ...
Support Center